(thirdQuint)A Phase I Study to Evaluate Safety, Tolerability and Pharmacokinetics of ONO-4053 in Healthy Volunteers.

 Ono Pharma UK Ltd is the European subsidiary of Ono Pharmaceutical Co.

 Ltd.

 As the European Legal Representative of Ono Pharmaceutical Co.

 Ltd, Ono Pharma UK Ltd is carrying out this study.

 This is a clinical study of ONO-4053 in healthy volunteers.

 This study consists of three parts.

 Part A will investigate the safety, tolerability and pharmacokinetics when single ascending doses of ONO-4053 are administered in a double-blind manner.

 Part B will investigate the pharmacokinetics of ONO-4053 in the fed and fasted state in an open-label manner.

 Part C will investigate the safety, tolerability and pharmacokinetics when multiple ascending doses of ONO-4053 are administered in a double-blind manner.

 Doses for Part B and C will be determined after data from Part A are available.

.

 A Phase I Study to Evaluate Safety, Tolerability and Pharmacokinetics of ONO-4053 in Healthy Volunteers@highlight

The primary objective of this study is to evaluate the safety and tolerability of ONO-4053 across ascending single and multiple doses in healthy adult male and female subjects.

 The secondary objective of the study is to characterize the pharmacokinetic profile of ONO-4053 in healthy adult male and female subjects.

